Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Boehringer Ingelheim

Thumbnail
March 31, 2021

Radiotherapeutics remain in the deal-making frame

A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.

Thumbnail
March 29, 2021

The world’s first multiple myeloma cell therapy has it all to do

Article image
Vantage logo
March 26, 2021

Boehringer’s big cancer reveal draws near

The company might finally become an oncology player.

Article image
Vantage logo
March 25, 2021

Bristol is no Lag3-ard

Article image
Vantage logo
March 24, 2021

Better late than never for Boehringer in Covid-19

Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.

Article image
Vantage logo
March 08, 2021

Anaptysbio fails to excite ahead of pivotal push

Article image
Vantage logo
February 23, 2021

Merck & Co makes the accelerated approval pathway its own

Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.

Article image
Vantage logo
February 11, 2021

Gilead’s Galapagos hopes now rest on Toledo

Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.

Article image
Vantage logo
February 03, 2021

Reality Bites for Amgen’s bispecifics

Article image
Vantage logo
January 25, 2021

Aurinia adds icing to the cake with clean lupus approval

Article image
Vantage logo
January 15, 2021

The biotech resurrection continues

Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.